Q1 2026 Regeneron Pharmaceuticals Inc Earnings Call Transcript

Apr 29, 2026 / 12:30PM GMT

Release Date Price: $676.28 (-8.37%)

Transcript 10-Q8-K

Key Points

Positve

Regeneron Pharmaceuticals Inc (REGN) reported a 19% increase in total revenues and a 15% increase in non-GAAP earnings per share, demonstrating strong financial performance.
Global Dupixent net sales increased by 31% on a constant currency basis, reaching $4.9 billion, driven by strong demand across multiple approved indications and geographies.
EYLEA HD US net product sales grew 52% year-over-year to $468 million, with encouraging physician adoption reflecting confidence in its clinical profile.
The company received FDA approval for Otarmeni for genetic hearing loss, marking a significant milestone for patients with this ultra-rare condition.
Regeneron Pharmaceuticals Inc (REGN) announced a new $3 billion share repurchase program, reflecting confidence in its business and financial position.

Negative

The FDA did not act by the April 2026 PDUFA date for the company's regulatory application for a second contract manufacturer for the EYLEA HD pre-filled syringe, leaving the application pending.
EYLEA US net sales declined by 36% year-over-year, reflecting ongoing conversion to EYLEA HD, competitive pressures, and patient affordability issues.
There was a temporary interruption in bulk manufacturing at the Limerick, Ireland site, negatively impacting GAAP gross margin.
Regeneron Pharmaceuticals Inc (REGN) faces competition in the multiple myeloma space, with concerns about infection risks associated with BCMA bispecifics.
The company is navigating challenges in the regulatory process for its next-generation I&I assets, with ongoing discussions with the FDA.

Operator

Welcome to the Regeneron Pharmaceuticals first-quarter 2026 earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) Please note this conference is being recorded.

I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Ryan Crowe

Regeneron Pharmaceuticals In - Senior Vice President of Investor Relations & Strategic Analysis

Thank you, Kevin. Good morning, good afternoon and good evening to everyone listening around the world. Thank you for your interest in Regeneron and welcome to our first-quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes.

Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.